The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting to read "The red flags here are the company promotes itself far too much whilst delivering no substance, professional outfits like Proactive promote it & Bel is a TR1 holder who does so similarly yet it delivers nothing."
https://twitter.com/TheLongerGame/status/1621457003242557440
I'm not sure it was that low? Where do you read that, could you post a link to the source of your info please. Like who is the 'someone'???
My own view, it's just taking too long to get anything substantial out of ROQ that big pharma might want to buy up or buy into
That should be 3rd Feb 2023 of course - lol
Another 50,000 dumped, TR-1 coming soon?
My view is that ROQ haven't produced enough to get the big pharma's interested as of 3rd Feb 2022. We can see what the future brings, but going around conferences presenting papers makes me suspicious.
Going the other way now.
Someone is very keen to soak up the free float here to get things going. I wonder who that could be? Another TR-1 this week?
Still doing the rounds talking about it, rather than delivering it. There has to be some substance behind the talk surely? At what point do they actually start delivering something that the big pharma's will want to buy? We've been told on Twitter for more than a year that this is gonna come good. I don't see it anytime soon, I'm sure it will come good if enough people work collaboratively to get it there.
Jam is one thing, someone buying up as much of the free float as possible is another but delivering is what they need to do, not just test tube results
Happy with the RNS looking good this year
Very good RNS, time will tell but 2023 should be a very interesting year for ROQ with plenty of news/updates.
.....kicking in I see.
Let's hope the next RNS is about delivering something rather than jam tomorrow. Although it may well be a TR-1 !!!!!
Been watching this so think it's time to buy a few I feel
Feels like he's still buying and expect another TR1
And there we have it.
lumpy buys going through
Davies,
Did you sell your 50k this morning?
This has been promoted on twitter for almost 17 months, with same dribble that is will come good, but still it sits here at 6.875p.
It may come good, and I'm sure Twitterarti will blow smoke up some individuals a r s e if when it does, but please give it a rest. I'm certainly desensitised by all the roq posting on twitter.
More talking taking place, lots of jam tomorrow. They need to deliver.
The section which is key for me is: 'meeting a number of the leading large pharmaceutical companies to introduce the Company and present our programs'. Clearly there are risks, but fully funded and low mcap provide a massive upside potential. I'm holding and waiting, time will tell if I'm correct. DYOR
Nothing much in that update
With all the talking, not much delivering and now all the conference papers being presented. For me, in my opinion, this begs the question, is this feeling like a UK version of Theranos to anyone else? Just my opinion, but ROQ need to start delivering in 2023 if they want a big pharma to buy them out.
“…With biotech stocks down and having suffered the industry’s worst bear market since the 2000s, is Rocquefort Therapeutics worth a look at a 52 week low?…”
https://total-market-solutions.com/2022/12/roquefort-therapeutics-plc/
And also this is main market so clearly cant read either
Youre obviously thick!!
TM1
GST
Exactly the same today
ITS STANDARD